PDE3A and glioblastoma: In order to validate velcrin sensitivity in preclinical glioblastoma models that faithfully recapitulate genomic and transcriptomic profiles of primary tumors, we analyzed PDE3A and SLFN12 expression levels in glioblastoma neurospheres23 from the Dana Farber Center for Patient-Derived Models and the Broad Institute Cancer Cell Line Factory (Figure 2G and H, Supplementary Table 2, 3 and Figure 3).24 We selected the neurosphere models, BT288L, BT856, BT294, BT228, and BT359 (Figure 2G and H, Supplementary Table 4), with a range of PDE3A expression levels, for validation of velcrin sensitivity.